Qube Research & Technologies LTD Protalix Bio Therapeutics, Inc. Transaction History
Qube Research & Technologies LTD
- $62.3 Billion
- Q2 2024
A detailed history of Qube Research & Technologies LTD transactions in Protalix Bio Therapeutics, Inc. stock. As of the latest transaction made, Qube Research & Technologies LTD holds 121,030 shares of PLX stock, worth $140,394. This represents 0.0% of its overall portfolio holdings.
Number of Shares
121,030Holding current value
$140,394% of portfolio
0.0%Shares
1 transactions
Others Institutions Holding PLX
# of Institutions
63Shares Held
5.83MCall Options Held
103KPut Options Held
4.6K-
Israel Englander Millennium Management LLC | New York, Ny811KShares$940,9450.0% of portfolio
-
Jim Simons Renaissance Technologies LLC | New York, Ny805KShares$933,3350.0% of portfolio
-
Goldman Sachs Group Inc New York, NY462KShares$535,8710.0% of portfolio
-
Gsa Capital Partners LLP London, X0435KShares$504,8470.03% of portfolio
-
Northern Trust Corp Chicago, IL423KShares$490,9270.0% of portfolio
About Protalix BioTherapeutics, Inc.
- Ticker PLX
- Exchange NYSE
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 49,753,400
- Market Cap $57.7M
- Description
- Protalix BioTherapeutics, Inc., a biopharmaceutical company, focuses on the development and commercialization of recombinant therapeutic proteins based on its proprietary ProCellEx plant cell-based protein expression system in the United States, Australia, Canada, Israel, Brazil, Russia, Turkey, and internationally. The company offers Elelyso fo...